Klinikum Wuerzburg Mitte gGmbH
- Address
- lock Available on a paid plan
Neoplasms (Oncology)
At Klinikum Wuerzburg Mitte gGmbH, investigators are studying metastatic non‑small cell lung cancer with the aim of testing new targeted agents and immunotherapy combinations to improve survival outcomes.
- Evaluation of ROS1‑positive tumor targeting therapies
- Combination of checkpoint inhibitors with antibody‑drug conjugates
- Assessment of progression‑free survival as a primary endpoint
- Comparison of overall survival benefits across treatment arms
Results are expected to shape future lung‑cancer treatment guidelines and provide new options for patients with advanced disease.
Nervous System Diseases
The research team is also dedicated to advancing care for multiple sclerosis, focusing on the long‑term safety and tolerability of oral therapies for both relapsing and progressive forms of the disease.
- Long‑term safety monitoring of BTK inhibitor treatment
- Inclusion of relapsing‑remitting and progressive patient cohorts
- Evaluation of neurological function preservation
- Impact on patients’ quality of life and daily activities
Findings will help clinicians choose safer, more effective strategies for managing chronic nervous‑system disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 39 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1AstraZeneca AB3active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB7trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Wuerzburg Mitte gGmbH
lock Showing 1 of 28 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Multi-center, Randomized, Double-blind, Placebo controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Immunovant Sciences GmbH | Phase II | Recruiting | Nov 2025 | — |
IMP list
lock Showing 1 of 39 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 9 | Unknown | 2018-04-04 | 2025-10-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.